Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Predictors Of Response ◽

Rna And Dna ◽

Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

10.1158/1538-7445.sabcs16-s3-05 ◽

2017 ◽

Author(s):

M Tanioka ◽

C Fan ◽

LA Carey ◽

T Hyslop ◽

BN Pitcher ◽

...

Keyword(s):

Breast Cancer ◽

Genomic Data ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Integrated Analysis ◽

Her2 Positive ◽

Phase Iii Trial ◽

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

Annals of Oncology ◽

10.1093/annonc/mdw622 ◽

2017 ◽

Vol 28 (2) ◽

pp. 305-312 ◽

Cited By ~ 9

Author(s):

O. Pagani ◽

D. Klingbiel ◽

T. Ruhstaller ◽

F. Nolè ◽

S. Eppenberger ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽

Letter to the editor on ‘Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial’

Annals of Oncology ◽

10.1093/annonc/mdu030 ◽

2014 ◽

Vol 25 (4) ◽

pp. 909-910 ◽

Cited By ~ 1

Author(s):

P.A. Barry ◽

G. Schiavon ◽

F.A. MacNeill

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Surgical Management ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽

Factors Associated ◽

Letter To The Editor ◽

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.506 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 506-506 ◽

Cited By ~ 7

Author(s):

Lisa A. Carey ◽

William Thomas Barry ◽

Brandy Pitcher ◽

Katherine A. Hoadley ◽

Maggie Chon U. Cheang ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Phase Iii Trial ◽

Gene Expression Signatures ◽

Post Therapy ◽

Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.056 ◽

2008 ◽

Vol 8 (5) ◽

pp. 453-456 ◽

Cited By ~ 38

Author(s):

Valentina Guarneri ◽

Antonio Frassoldati ◽

Paolo Bruzzi ◽

Roberto D'Amico ◽

Maurizio Belfiglio ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽

Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

10.1158/1538-7445.sabcs14-s3-06 ◽

2015 ◽

Cited By ~ 3

Author(s):

Katherine A Hoadley ◽

William T Barry ◽

Brandelyn N Pitcher ◽

Joel S Parker ◽

Matthew D Wilkerson ◽

...

Keyword(s):

Breast Cancer ◽

Mutational Analysis ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Phase Iii Trial ◽

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

10.1158/1538-7445.sabcs16-s3-06 ◽

2017 ◽

Cited By ~ 9

Author(s):

MF Rimawi ◽

RS Cecchini ◽

P Rastogi ◽

CE Geyer ◽

L Fehrenbacher ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Estrogen Deprivation ◽

Her2 Positive ◽

Phase Iii Trial ◽

B 52 ◽

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

Annals of Oncology ◽

10.1093/annonc/mdu034 ◽

2014 ◽

Vol 25 (4) ◽

pp. 910-911 ◽

Cited By ~ 6

Author(s):

C. Criscitiello ◽

H.A. Azim ◽

E. de Azambuja ◽

I.T. Rubio

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Surgical Management ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽

Factors Affecting ◽

Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

Annals of Oncology ◽

10.1093/annonc/mdz416 ◽

2019 ◽

Vol 30 ◽

pp. ix1

Author(s):

C. Huang ◽

Y. Yang ◽

A. Kwong ◽

S.-C. Chen ◽

L.-M. Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Invasive Disease ◽

Phase Iii ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99

10.1158/1538-7445.sabcs14-p4-15-11 ◽

2015 ◽

Author(s):

Olivia Pagani ◽

Dirk Klingbiel ◽

Thomas Ruhstaller ◽

Franco Nolè ◽

Serenella Eppenberger ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽